Show simple item record

dc.contributor.authorJahromi, Leila Pourtalebi
dc.contributor.authorShahbazi, Mohammad Ali
dc.contributor.authorMaleki, Aziz
dc.contributor.authorAzadi, Amir
dc.contributor.authorSantos, Hélder A.
dc.date.accessioned2021-03-31T09:33:10Z
dc.date.available2021-03-31T09:33:10Z
dc.date.issued2021-01-01
dc.identifier.citationAdvanced Science,(2021), DOI:10.1002/advs.202002499.en_US
dc.identifier.doi10.1002/advs.202002499
dc.identifier.urihttp://hdl.handle.net/10033/622807
dc.description.abstractOver the past decades, considerable attention has been dedicated to the exploitation of diverse immune cells as therapeutic and/or diagnostic cell‐based microrobots for hard‐to‐treat disorders. To date, a plethora of therapeutics based on alive immune cells, surface‐engineered immune cells, immunocytes’ cell membranes, leukocyte‐derived extracellular vesicles or exosomes, and artificial immune cells have been investigated and a few have been introduced into the market. These systems take advantage of the unique characteristics and functions of immune cells, including their presence in circulating blood and various tissues, complex crosstalk properties, high affinity to different self and foreign markers, unique potential of their on‐demand navigation and activity, production of a variety of chemokines/cytokines, as well as being cytotoxic in particular conditions. Here, the latest progress in the development of engineered therapeutics and diagnostics inspired by immune cells to ameliorate cancer, inflammatory conditions, autoimmune diseases, neurodegenerative disorders, cardiovascular complications, and infectious diseases is reviewed, and finally, the perspective for their clinical application is delineated.en_US
dc.description.sponsorshipAcademy of Finlanden_US
dc.language.isoenen_US
dc.publisherWiley-VCHen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectartificial dendritic cell and extracellular vesicleen_US
dc.subjectbiomimetic drug deliveryen_US
dc.subjectengineered immune cellen_US
dc.subjectimmune cell membraneen_US
dc.subjectnanomedicineen_US
dc.titleChemically Engineered Immune Cell-Derived Microrobots and Biomimetic Nanoparticles: Emerging Biodiagnostic and Therapeutic Toolsen_US
dc.typeReviewen_US
dc.identifier.eissn21983844
dc.contributor.departmentHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.en_US
dc.identifier.journalAdvanced Scienceen_US
dc.identifier.eid2-s2.0-85101839525
dc.identifier.scopusidSCOPUS_ID:85101839525
refterms.dateFOA2021-03-31T09:33:11Z
dc.source.journaltitleAdvanced Science


Files in this item

Thumbnail
Name:
Jahromi et al.pdf
Size:
18.73Mb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International